C=x Bonded Directly To The Five-membered Hetero Ring By Nonionic Bonding (x Is Chalcogen) Patents (Class 514/423)
  • PRODRUGS OF INHIBITORS OF PLASMA KALLIKREIN
    Publication number: 20140128436
    Abstract: The present invention provides prodrugs of compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating plasma kallikrein dependent diseases or conditions, for example, diabetic macular edema, with the prodrugs having the formula:
    Type: Application
    Filed: November 8, 2013
    Publication date: May 8, 2014
    Applicant: ActiveSite Pharmaceuticals, Inc.
    Inventors: Sukanto Sinha, Tamie Jo Chilcote
  • 5-CARBAMOYL-ADAMANTAN-2-YL AMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND PREPARATION PROCESS THEREOF
    Publication number: 20140128427
    Abstract: Provided are a novel derivative of 5-carbamoyl adamantan-2-yl amide or a pharmaceutically acceptable salt thereof, and a pharmaceutical use thereof for inhibiting the activity of 11?-hydroxystreroid dehydrogenase type 1 (11b-HSD1) or for preventing and/or treating various diseases mediated by 11?-hydroxystreroid dehydrogenase type 1.
    Type: Application
    Filed: June 11, 2012
    Publication date: May 8, 2014
    Applicant: SK BIOPHARMACEUTICALS CO., LTD.
    Inventors: Coo-Min Chung, Choon-Ho Ryu, Yoon-Kyeong Lee, Jin-Sook Moon, Hye-Sung Lee, Seon-Jeong Lee, Kyung-Seok Oh
  • HETEROCYCLIC INHIBITORS OF NECROPTOSIS
    Publication number: 20140128437
    Abstract: The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-?) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-? induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.
    Type: Application
    Filed: January 10, 2014
    Publication date: May 8, 2014
    Applicants: President and Fellows of Harvard College, TRUSTEES OF BOSTON UNIVERSITY, THE BRIGHAM AND WOMEN'S HOSPITAL, INC., Tufts University
    Inventors: Gregory D. Cuny, Xin Teng, Junying Yuan, Alexei Degterrev, John A. Proco, JR.
  • Pyrrolidinone carboxamide derivatives
    Patent number: 8716494
    Abstract: Pyrrolidinone carboxamide compounds are provided that are useful for inhibiting the binding of ligands to the ChemR23 receptor.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: May 6, 2014
    Assignee: ChemoCentryx, Inc.
    Inventors: Trevor T. Charvat, Hiufung Chu, Antoni Krasinski, Christopher W. Lange, Manmohan R. Leleti, Jay P. Powers, Sreenivas Punna, Timothy J. Sullivan, Solomon Ungashe
  • SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES
    Publication number: 20140121217
    Abstract: The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein A, Y, L, R1, W1 and W2 are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
    Type: Application
    Filed: January 2, 2014
    Publication date: May 1, 2014
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Shoujun Chen, Lijun Sun, Jun Jiang, Yu Xie
  • NOVEL CONJUGATES OF POLYUNSATURATED FATTY ACIDS WITH AMINES AND THERAPEUTIC USES THEREOF
    Publication number: 20140121260
    Abstract: The present application discloses conjugates comprising an aminic moiety covalently linked to a hydrophobic moiety, through an amidic bond, which are selective inhibitors of COX-2 enzyme and can be beneficially used in the treatment of various inflammatory disease or disorder and cancer.
    Type: Application
    Filed: January 6, 2014
    Publication date: May 1, 2014
    Applicant: MedWell Laboratories Ltd.
    Inventors: Taher NASSAR, Raiyn Nureldin, Rayan Anwar
  • THERAPEUTICS FOR AGE-RELATED MACULAR DEGENERATION
    Publication number: 20140120112
    Abstract: The invention provides compositions and methods of predicting a subject's risk of developing age-related macular degeneration (AMD) and methods of treating, delaying, or preventing the development and progression of AMD.
    Type: Application
    Filed: December 19, 2013
    Publication date: May 1, 2014
    Inventor: Kameran Lashkari
  • COMBINATION COMPRISING S-[2-([[1-(2-ETHYLBUTYL)CYCLOHEXYL] CARBONYL]AMINO)PHENYL] 2-METHYLPROPANETHIOATE AND AN HMG COA REDUCTASE INHIBITOR
    Publication number: 20140121229
    Abstract: The invention provides a combination comprising (a) S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate or prodrug of the active form thereof, and (b) at least one HMG CoA reductase inhibitor. Also provided are a pharmaceutical composition, package, and a kit comprising the aforementioned active ingredients, as well as a method for treatment and prophylaxis of a cardiovascular disorder involving the use of the aforementioned active ingredients.
    Type: Application
    Filed: May 3, 2013
    Publication date: May 1, 2014
    Applicant: Japan Tobacco Inc.
    Inventor: Japan Tobacco Inc.
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF JUVENILE NEURONAL CEROID LIPOFUSCINOSIS AND RELATED DISORDERS
    Publication number: 20140121166
    Abstract: Provided are materials and methods for the prevention and treatment of Juvenile Neuronal Ceroid Lipofuscinosis comprising administration of an effective amount of at least one of a hemi-channel inhibitor or a phosphodiesterase-4 inhibitor. In some embodiments, the methods comprise administration of an effective amount of each of a hemi-channel inhibitor and a phosphodiesterase-4 inhibitor. Also provided are pharmaceutical compositions comprising a hemi-channel inhibitor or a phosphodiesterase-4 inhibitor, as well as kits comprising at least one effective dose of a hemi-channel inhibitor or a phosphodiesterase-4 inhibitor or a combination of both.
    Type: Application
    Filed: October 29, 2013
    Publication date: May 1, 2014
    Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
    Inventor: Tammy Kielian
  • Crystalline form of zofenopril calcium
    Patent number: 8710241
    Abstract: The present invention relates to a novel anhydrous crystalline form of zofenopril calcium of formula (I), chemically known as (4S)-1-[(2S)-3-(benzoylthio)-2-methylpropionyl]-4-(phenylthio)-L-proline calcium salt or hemi-calcium salt. The present invention further relates to a process for the preparation of the new crystalline form of zofenopril calcium, its use in pharmaceutical compositions and the use of the new crystalline form and compositions in the treatment of hypertension and various other diseases.
    Type: Grant
    Filed: August 8, 2008
    Date of Patent: April 29, 2014
    Assignee: Generics [UK]Limited
    Inventor: Axel Becker
  • Methods of enhancing diabetes resolution
    Patent number: 8710002
    Abstract: Disclosed are compositions and methods for increasing diabetes resolution in a diabetic patient having undergone gastric restrictive surgery, entailing use of active agent that produces an incretin-like effect in the patient.
    Type: Grant
    Filed: November 21, 2008
    Date of Patent: April 29, 2014
    Inventor: Michael Rothkopf
  • Drug Combinations and Uses
    Publication number: 20140113948
    Abstract: The present specification discloses compositions comprising a pharmaceutical composition to reduce or maintain LDL and/or cholesterol levels in an individual and a plurality of therapeutic compounds to increase or maintain HDL levels in an individual. The present specification also discloses a treatment protocol wherein a pharmaceutical composition is administered to an individual on a schedule wherein the pharmaceutical composition is provided for a period of time and then not provided to the individual and this treatment protocol is repeated for the term of the individual's treatment.
    Type: Application
    Filed: October 24, 2013
    Publication date: April 24, 2014
    Applicant: BIOCOPEA LIMITED
    Inventors: John Brew, Robin Mark Bannister
  • Process for the preparation of amorphous calcium salt of atorvastatin
    Patent number: 8697741
    Abstract: A process for the preparation of amorphous atorvastatin calcium. The process includes providing a reaction mixture having a pH between 6.5 and 8.0 containing a sodium salt of atorvastatin and tetrahydrofuran. A non-cyclic chlorinated organic solvent selected from the group consisting of dichloromethane, trichloroethane, tetrachloroethane and chloroform or addition of cyclic hydrocarbon solvent selected from the group consisting of cyclohexane, cyclopentane and methyl cyclohexane is added to provide a mixture of organic solvents. An equivalent or an excess quantity of a source of calcium ions selected from the group consisting of calcium acetate and calcium chloride is added. Amorphous atorvastatin calcium is isolated from an organic phase comprising the mixture of organic solvents.
    Type: Grant
    Filed: March 4, 2009
    Date of Patent: April 15, 2014
    Assignee: LEK Pharmaceutical D.D.
    Inventors: Ljubomir Antoncic, Gorazd Sorsak, Anton Copar
  • Enalapril Compositions
    Publication number: 20140100260
    Abstract: Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Application
    Filed: June 10, 2013
    Publication date: April 10, 2014
    Inventors: Lian G. Rajewski, Roger A. Rajewski, John L. Haslam, Kathleen Heppert, Michael C. Beckloff, Frank Segrave, Robert Mauro, Peter Colabuono
  • C17-ALKANEDIYL AND ALKENEDIYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF
    Publication number: 20140100227
    Abstract: Disclosed herein are novel C17-alkanediyl and alkenediyl derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided.
    Type: Application
    Filed: September 10, 2013
    Publication date: April 10, 2014
    Applicant: REATA PHARMACEUTICALS, INC.
    Inventors: Christopher F. BENDER, Xin JIANG, Eric ANDERSON, Melean VISNICK
  • Prodrugs of inhibitors of plasma kallikrein
    Patent number: 8691861
    Abstract: This invention provides new pharmaceutically useful compounds that are prodrugs of inhibitors of plasma kallikrein and methods and compositions for preventing or treating plasma kallikrein dependent diseases or conditions, such as diabetic macular edema or hemorrhagic stroke, by administering prodrugs of the formula:
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: April 8, 2014
    Assignee: ActiveSite Pharmaceuticals, Inc.
    Inventors: Sukanto Sinha, Tamie Jo Chilcote, Joghee Raju Suresh, Sriram Narasimhan
  • METHODS OF LOWERING PROPROTEIN CONVERSATE SUBTILISIN/KEXIN TYPE 9 (PCSK9)
    Publication number: 20140093513
    Abstract: The invention relates to new methods of modulating cholesterol by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) with fatty acid derivatives; and new methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid derivative. The present invention is also directed to fatty acid bioative derivatives and their use in the treatment of metabolic diseases.
    Type: Application
    Filed: May 24, 2013
    Publication date: April 3, 2014
    Applicant: Catabasis Pharmaceuticals, Inc.
    Inventors: Jill C. Milne, Michael R. Jirousek, Chi B. Vu
  • AMINO ACID COMPOSITION
    Publication number: 20140094434
    Abstract: Amino acid compositions containing a carbohydrate and any one or more kinds of alanine, proline and glycine as amino acid can suppress a rapid increase in the blood glucose level immediately after ingestion and a decrease in the blood glucose level due to prolonged exercise, and can improve exercise performance. In addition, the present invention provides inhibitors of an increase in the blood glucose level immediately after carbohydrate ingestion, an inhibitor of a decrease in the blood glucose level due to a prolonged exercise, and an exercise performance improver. Therefore, the present invention provides an energy supplement useful for those who exercise (particularly prolonged exercise).
    Type: Application
    Filed: December 6, 2013
    Publication date: April 3, 2014
    Applicant: AJINOMOTO CO., INC.
    Inventors: Yuri HIRABAYASHI, Chie FURUTA, Yoshihito NOGUSA, Katsuya SUZUKI, Hisamine KOBAYASHI
  • Solid compositions
    Patent number: 8686026
    Abstract: The present invention features solid compositions comprising amorphous Compound I. For instance, Compound I may be formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: April 1, 2014
    Assignee: AbbVie Inc.
    Inventors: Bernd Liepold, Tina Jung, Peter Hölig, Rudolf Schroeder, Nancy E. Sever, Justin S. Lafountaine, Brent D. Sinclair, Yi Gao, Jianwei Wu
  • Process for forming amorphous atorvastatin
    Patent number: 8686163
    Abstract: A process for forming amorphous atorvastatin comprising the steps of dissolving atorvastatin in a non-hydroxylic solvent and removing the solvent by freeze-drying, as well as processes of dissolving atorvastatin in a hydroxylic solvent with a solubilizing agent or an alkalizing agent or an antioxidant and removing the solvent by freeze-drying to afford amorphous atorvastatin.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: April 1, 2014
    Assignee: Pfizer Inc.
    Inventors: Antone J deBettencourt, III, Evgenyi Shalaev, George J. Quallich, Carl B. Ziegler, Jr.
  • FLUORINATED ARYLALKYLAMINOCARBOXAMIDE DERIVATIVES
    Publication number: 20140088074
    Abstract: Fluorinated arylalkylaminocarboxamide derivatives of formula (I) are described wherein W, J, n, R1, R2, R3, R4, R5 and R6 have the meanings as defined in the specification and pharmaceutically salts thereof, pharmaceutical compositions containing them as active ingredients and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies, including neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urological, and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.
    Type: Application
    Filed: May 29, 2012
    Publication date: March 27, 2014
    Applicant: NEWRON PHARMACEUTICALS S.P.A.
    Inventor: Paolo Pevarello
  • Sulfonylhydrazide compounds for treating proliferative disorders
    Patent number: 8680100
    Abstract: The present invention is directed to compounds represented by structural formula (I), or a pharmaceutically acceptable salt or a transition metal chelate, coordinate or complex thereof or a transition metal chelate, coordinate or complex of a deprotonated form of the compound. Pharmaceutical composition and method of use for these compounds are also included.
    Type: Grant
    Filed: December 1, 2009
    Date of Patent: March 25, 2014
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Jun Jiang, Teresa Kowalczyk-Przewloka, Stefan M. Schweizer, Zhi-Qiang Xia, Shoujun Chen, Christopher Borella, Lijun Sun
  • Fungicide N-cycloalkyl-N-biphenylmethyl-carboxamide derivatives
    Patent number: 8680127
    Abstract: The present invention relates to N-cycloalkyl-N-biphenylmethyl-carboxamide derivatives of formula (I) wherein A, Z1, Z2, Z3, X, n, Y and m represent various substituents, their process of preparation, preparation intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: March 25, 2014
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Philippe Desbordes, Ralf Dunkel, Stephanie Gary, Marie-Claire Grosjean-Cournoyer, Benoit Hartmann, Philippe Rinolfi, Jean-Pierre Vors, Rachel Rama
  • COMPOSITIONS FOR INCREASING HUMAN GROWTH HORMONE LEVELS
    Publication number: 20140079831
    Abstract: Embodiments of the invention generally relate to supplements for increasing human growth hormone (hGH) levels in healthy human beings.
    Type: Application
    Filed: September 20, 2012
    Publication date: March 20, 2014
    Applicant: Quality IP Holdings, LLC
    Inventors: Amy L. Heaton, Mitchell K. Friedlander, Dennis Gay
  • METHODS FOR INCREASING ENDURANCE AND FAT METABOLISM IN HUMANS
    Publication number: 20140080888
    Abstract: Embodiments of the invention generally relate to methods and supplements for increasing endurance and fat metabolism in human beings.
    Type: Application
    Filed: September 20, 2012
    Publication date: March 20, 2014
    Applicant: Basic Research L.L.C.
    Inventor: Basic Research L.L.C.
  • METHODS AND COMPOSITIONS FOR INCREASING SEX STEROIDS AND GROWTH HORMONES
    Publication number: 20140079829
    Abstract: Embodiments of the invention generally relate to methods and supplements for increasing sex steroids and human growth hormone in a human being.
    Type: Application
    Filed: September 20, 2012
    Publication date: March 20, 2014
    Applicant: Basic Research L.L.C.
    Inventors: Amy L. HEATON, Mitchell K. Friedlander, Dennis Gay
  • METHODS FOR IMPROVING THYROID FUNCTION IN A SUBJECT
    Publication number: 20140079830
    Abstract: Embodiments of the invention generally relate to methods for improving thyroid function in healthy human beings.
    Type: Application
    Filed: September 20, 2012
    Publication date: March 20, 2014
    Applicant: Basic Research L.L.C.
    Inventor: Basic Research L.L.C.
  • Statin and Omega-3 Fatty Acids for Lipid Therapy
    Publication number: 20140080889
    Abstract: A method and composition for lipid therapy. In some embodiments, the method comprises providing a subject group having a baseline triglyceride level of 200 to 499 mg/dl and being at or near its low-density lipoprotein cholesterol (LDL-C) level goal, and reducing the triglyceride level and the non-high-density lipoprotein cholesterol (non-HDL-C) level of the subject group as compared to treatment with a 3-hydroxy-3-methyl glutaryl coenzyme A (HMG CoA) inhibitor alone, by administering to the subject group an effective amount of an HMG CoA inhibitor and a composition comprising omega-3 fatty acids.
    Type: Application
    Filed: November 25, 2013
    Publication date: March 20, 2014
    Applicant: GlaxoSmithKline, LLC
    Inventors: George BOBOTAS, Roelof M. Rongen, Egil Bodd, Hogne Vik
  • PHARMACEUTICAL COMPOSITION COMPRISING AN OMEGA-3 FATTY ACID AND A HYDROXY-DERIVATIVE OF A STATIN AND METHODS OF USING SAME
    Publication number: 20140080850
    Abstract: In various embodiments, the present invention provides compositions and methods for treating and/or preventing a cardiovascular-related disease in subject in need thereof.
    Type: Application
    Filed: June 3, 2013
    Publication date: March 20, 2014
    Inventor: Richard Preston Mason
  • METHODS FOR TREATING POST-TRAUMATIC STRESS DISORDER
    Publication number: 20140079823
    Abstract: Embodiments herein relate to nutritional supplements for treating post-traumatic stress disorder in human beings, and to methods of using the same. In particular examples, the nutritional supplement comprises an amino acid secretagogue composition.
    Type: Application
    Filed: September 19, 2012
    Publication date: March 20, 2014
    Applicant: Basic Research L.L.C.
    Inventor: Basic Research L.L.C.
  • METHODS FOR INCREASING HUMAN GROWTH HORMONE LEVELS
    Publication number: 20140079828
    Abstract: Embodiments of the invention generally relate to methods and supplements for increasing human growth hormone (hGH) levels in healthy human beings.
    Type: Application
    Filed: September 20, 2012
    Publication date: March 20, 2014
    Applicant: Quality IP Holdings, LLC
    Inventors: Amy L. Heaton, Mitchell K. Friedlander, Dennis Gay
  • Inhibitors of Histone Deacetylase
    Publication number: 20140080802
    Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R2a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.
    Type: Application
    Filed: October 28, 2013
    Publication date: March 20, 2014
    Inventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Li-Huei Tsai, Stephen Haggarty, Yan-Ling Zhang
  • METHODS FOR IMPROVING LINEAR GROWTH RESPONSE IN CHILDREN
    Publication number: 20140080887
    Abstract: Embodiments of the invention generally relate to methods and supplements for increasing linear growth in borderline GH deficient and non-GH deficient children.
    Type: Application
    Filed: September 19, 2012
    Publication date: March 20, 2014
    Applicant: Basic Research L.L.C.
    Inventors: Amy L. Heaton, Mitchell K. Friedlander, Dennis Gay
  • METHODS FOR IMPROVING HEALTH IN CANINES
    Publication number: 20140079825
    Abstract: A method of improving health in a canine includes administering to the canine a nutritional supplement comprising an amino acid secretagogue composition, which stimulates the pituitary gland of the canines to produce growth hormone. The nutritional supplement may be administered orally. The nutritional supplement may comprise L-arginine hydrochloride, Oxo-proline, L-lysine hydrochloride, and cysteine. When desired, the nutritional supplement may consist essentially of L-arginine hydrochloride, Oxo-proline, L-lysine hydrochloride, N-acetyl-L-cysteine, L-glutamine, and schizonepeta powder.
    Type: Application
    Filed: September 20, 2012
    Publication date: March 20, 2014
    Applicant: Basic Research L.L.C.
    Inventors: Amy L. HEATON, Mitchell K. Friedlander, Dennis Gay
  • METHODS FOR IMPROVING SLEEP EFFICIENCY IN HEALTHY HUMAN BEINGS
    Publication number: 20140079822
    Abstract: Embodiments of the invention generally relate to methods and supplements for improving sleep efficiency in human beings.
    Type: Application
    Filed: September 19, 2012
    Publication date: March 20, 2014
    Applicant: Basic Research L.L.C.
    Inventor: Basic Research L.L.C.
  • METHODS FOR IMPROVING HEALTH IN HUMANS
    Publication number: 20140079821
    Abstract: Embodiments of the invention generally relate to methods and supplements for improving the health of human beings.
    Type: Application
    Filed: September 19, 2012
    Publication date: March 20, 2014
    Applicant: Basic Research L.L.C.
    Inventor: Basic Research L.L.C.
  • COMPOSITIONS AND METHODS FOR INCREASING HUMAN GROWTH HORMONE LEVELS
    Publication number: 20140079826
    Abstract: Embodiments of the invention generally relate to methods and supplements for increasing human growth hormone (hGH) levels in healthy human beings.
    Type: Application
    Filed: September 20, 2012
    Publication date: March 20, 2014
    Applicant: Basic Research L.L.C.
    Inventors: Amy L. Heaton, Mitchell K. Friedlander, Dennis Gay
  • METHODS FOR IMPROVING HEALTH IN ANIMALS
    Publication number: 20140079827
    Abstract: A method of improving health in an animal includes administering to the animal a nutritional supplement comprising an amino acid secretagogue composition, which stimulates the pituitary gland in the animal to produce growth hormone. The nutritional supplement may be administered orally. The nutritional supplement may comprise L-arginine hydrochloride, L-pyroglutamic acid, L-lysine hydrochloride, and cysteine. When desired, the nutritional supplement may consist essentially of L-arginine hydrochloride, L-pyroglutamic acid, L-lysine hydrochloride, N-acetyl-L-cysteine, L-glutamine, and schizonepeta powder.
    Type: Application
    Filed: September 20, 2012
    Publication date: March 20, 2014
    Applicant: Basic Research L.L.C.
    Inventors: Amy L. Heaton, Mitchell K. Friedlander, Dennis Gay
  • Inhibitors of histone deacetylase
    Patent number: 8673911
    Abstract: This invention relates to compounds and methods for the inhibition of HDAC enzymatic activity. More particularly, the invention provides for compounds of formula (I), (I) and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein L, M, n, R, W, X and Y are as defined in the specification.
    Type: Grant
    Filed: November 3, 2008
    Date of Patent: March 18, 2014
    Assignee: MethylGene Inc.
    Inventors: Tammy Mallais, Oscar Moradei, Alain Ajamian, Pierre Tessier, David Smil, Sylvie Frechette, Silvana Leit, Patrick Beaulieu, Robert Deziel, John Mancuso
  • METHODS FOR DRUG SCREEN USING ZEBRAFISH MODEL AND THE COMPOUNDS SCREENED THEREFROM
    Publication number: 20140073611
    Abstract: The disclosure relates to a platform of using zebrafish in screening candidates for treating and/or preventing myopia and keratoconus disease. The disclosure is mainly based on that Lumican, one of several SLRPs, plays an important role in the regulation of fibrillogenesis or the genes affecting the size of eyeballs in zebrafish, in addition to playing an important role in clinical myopia. Therefore, the disclosure uses the established zebrafish model to further identify the drugs affecting the expression of lumican and collagen fibrillogenesis, and/or the regulation of eyeball size. These drugs are potential candidates for treating myopia and/or keratoconus disease.
    Type: Application
    Filed: May 21, 2013
    Publication date: March 13, 2014
    Applicant: National Taiwan University
    Inventors: I-Jong Wang, Wei-Ting Ho, Ting-Hsuan Chiang, I-Tsen Lin
  • GENETIC POLYMORPHISMS ASSOCIATED WITH CORONARY EVENTS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF
    Publication number: 20140072550
    Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with coronary heart disease (particularly myocardial infarction), aneurysm/dissection, and/or response to drug treatment, particularly statin treatment. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.
    Type: Application
    Filed: June 27, 2013
    Publication date: March 13, 2014
    Applicant: CELERA CORPORATION
    Inventors: Olga IAKOUBOVA, James J. DEVLIN, Carmen TONG, Charles ROWLAND
  • HETEROCYCLIC COMPOUND
    Publication number: 20140066420
    Abstract: The present invention relates to wherein each symbol is as defined in the specification. The compound of the present invention has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of disease and condition mediated by increased RBP4.
    Type: Application
    Filed: October 16, 2013
    Publication date: March 6, 2014
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Shizuo KASAI, Tomohiro KAKU, Masahiro KAMAURA
  • FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES
    Publication number: 20140066426
    Abstract: The invention relates to pyrrole carboxamides bearing a fluoromethyl-moiety as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
    Type: Application
    Filed: August 29, 2013
    Publication date: March 6, 2014
    Inventors: Stefan SCHUNK, Melanie REICH, Henning STEINHAGEN, Nils DAMANN, Michael HAURAND, Achim KLESS, Philip SKONE, Richard HAMLYN, Robert KIRBY, Marc ROGERS, Kathy SUTTON
  • METHODS AND COATINGS FOR TREATING BIOFILMS
    Publication number: 20140056952
    Abstract: Methods of treating or reducing biofilms, treating a biofilm-related disorder, and preventing biofilm formation using polyamines is described.
    Type: Application
    Filed: November 4, 2013
    Publication date: February 27, 2014
    Applicant: President and Fellows of Harvard College
    Inventors: Richard LOSICK, Illana KOLODKIN-GAL, Jon CLARDY, Shugeng CAO, Matt CABEEN, Roberto KOLTER, Liraz CHAI, Thomas BÖTTCHER
  • METHODS AND COMPOSITIONS FOR TREATING BIOFILMS
    Publication number: 20140056951
    Abstract: Methods of treating or reducing biofilms, treating a biofilm-related disorder, and preventing biofilm formation using polyamines is described.
    Type: Application
    Filed: November 4, 2013
    Publication date: February 27, 2014
    Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Richard LOSICK, Illana KOLODKIN-GAL, Jon CLARDY, Shugeng CAO, Matt CABEEN, Roberto KOLTER, Liraz CHAI, Thomas BÖTTCHER
  • NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE
    Publication number: 20140057873
    Abstract: There is provided amino acid ester compounds comprising at least one nitric oxide releasing group, pharmaceutically acceptable salts thereof and compositions thereof. These compounds involve an amino acid side-chain or an amino acid derivative thereof and a nitric oxide releasing group as depicted in the following structures: wherein R1 is either an ethyl or an amino acid side-chain group or an amino acid derivative thereof and R2 is an amino acid side-chain group or an amino acid derivative thereof and n is an integer from 1 to 10.
    Type: Application
    Filed: November 1, 2013
    Publication date: February 27, 2014
    Inventor: Michael Farber
  • Heterocyclic inhibitors of necroptosis
    Patent number: 8658689
    Abstract: The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-?) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-? induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.
    Type: Grant
    Filed: August 20, 2012
    Date of Patent: February 25, 2014
    Assignees: President and Fellows of Harvard College, The Brigham and Women's Hospital, Inc., Tufts University, Trustees of Boston University
    Inventors: Gregory D. Cuny, Xin Teng, Junying Yuan, Alexei Degterev, John A. Porco, Jr.
  • Methods for Predicting Cardiovascular Risks and Responsiveness to Statin Therapy Using SNPs
    Publication number: 20140044668
    Abstract: Methods and compositions for the effect of Cholesteryl ester transfer protein (CETP) polymorphisms on mRNA splicing, statin treatment outcome, response to CETP inhibitor drugs, and myocardial infarction risk are described.
    Type: Application
    Filed: February 15, 2012
    Publication date: February 13, 2014
    Applicant: THE OHIO STATE UNIVERSITY
    Inventors: Wolfgang Sadee, Audrey C. Papp
  • COMPOSITION AND METHOD FOR TREATMENT OF DIABETES
    Publication number: 20140045912
    Abstract: The present invention relates to a method of treating diabetes type II by delivery of butyric acid, bile acid, long chain fatty acid or glutamine to the colon by bypassing the upper digestive tract. The composition is combined either by the same or different route of administration with a DPP-IV inhibitor such as vildagliptin.
    Type: Application
    Filed: May 2, 2012
    Publication date: February 13, 2014
    Applicant: BIOKIER, INC
    Inventor: Jerzy Ryszard Szewczyk
  • INHIBITORS OF HISTONE DEACETYLASE
    Publication number: 20140045850
    Abstract: This invention relates to compounds and methods for the inhibition of HDAC enzymatic activity. More particularly, the invention provides for compounds of formula (I), (I) and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein L, M, n, R, W, X and Y are as defined in the specification.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 13, 2014
    Applicant: METHYLGENE INC.
    Inventor: METHYLGENE INC.